Asia's Cultivated Meat Industry Just Got a Playbook to Approve Products Without the Million-Dollar Paperwork

On October 12, a coalition of more than 30 scientists, regulators and industry specialists published a paper with an unusually practical goal: make cultivated meat cheaper to approve in Asia without making it less safe. The paper, from the APAC Regulatory Coordination Forum, proposes that regulators judge cultivated meat and seafood the way chemists judge a substance, with lab tests and compositional analysis, rather than defaulting to long-term animal feeding studies that cost roughly $213,400 and take more than a year each.

The document had circulated as a preprint since late 2025. Its formal publication was announced this month by Peter Yu, program director at the APAC Society for Cellular Agriculture, which runs the Forum together with the Good Food Institute APAC. The two organizations have already published joint guidance on cell lines and growth media. This new paper is the most ambitious step yet, a full proposed method for how a regulator should decide whether a cultivated product is safe to sell.

What the framework actually proposes

The method starts with a comparison: stack the cultivated product against its conventional equivalent and measure protein, fats, vitamins and minerals. Then audit every input that went into production, growth media, scaffolds and processing aids, to establish whether any residues remain at levels that could matter to a consumer. Further checks cover the stability of the cell line, potential allergens and contaminants such as heavy metals.

The authors' argument is straightforward. Cultivated products are manufactured in controlled facilities from known inputs, so most potential hazards can be measured directly with established lab tests and computer modeling rather than inferred from feeding trials in animals. Regulators already accept similar methods for precision fermentation ingredients and other novel foods, so the paper is asking Asia's food-safety agencies to apply an approach they largely use already, just not yet to meat grown from cells.

For producers, the difference is not abstract. Under the lab-based method, a company that changes a single production input, a different growth medium, a revised scaffold, could have that one component reassessed on its own instead of repeating a full study. In an industry where the production process is still being tuned year to year, that modularity turns regulatory approval from a restart-the-clock event into an iterative review.

Two-speed Asia

The paper lands in a region with sharply divided rules. The United States, Singapore, Australia and New Zealand, and Israel have all cleared cultivated products using the kind of evidence the paper describes. South Korea and Thailand, according to the paper, still require long-term feeding studies, though companies are reportedly in talks with the Thai Food and Drug Administration about alternatives.

That split has practical consequences for anyone trying to build a business. A single feeding study costing around $213,400 and consuming more than a year, based on a US EPA estimate cited in the paper, is a cost a seed-stage startup feels very differently than a multinational does. When every process tweak potentially triggers a fresh review cycle, caution wins and innovation slows.

The irony is that the markets demanding the most testing are also the ones courting the industry hardest. South Korea's Ministry of Food and Drug Safety is already accepting applications for cultivated meat approvals, and APAC-SCA polling of 1,110 South Koreans found 90 percent willing to try cultivated meat at least once, though only 5 percent said they would eat it regularly. Aleph Farms, the Israeli company, has already filed for approval in Thailand in partnership with Thai Union, betting on the country's regional ambitions.

Why the timing matters

The publication arrives as Asia's lead on cultivated meat approvals keeps widening. Singapore, the first country anywhere to clear cultivated meat, cleared two landmark products in 2026: Parima's cultivated duck in April, making it the first company approved across two species after its chicken cleared six months earlier, and Aleph Farms' cultivated thin-cut beef steak on August 4, the first regulatory clearance anywhere for cultivated beef.

Singapore's streak is a useful reminder of the paper's underlying point. Every one of those clearances was granted on the basis of compositional and process evidence, not year-long feeding trials, and the world has kept turning. The forum paper is essentially a proposal to make Singapore's implicit method explicit, portable and available to regulators across the region who have been waiting for a template.

"Importantly, this is not about lowering the safety bar. It is about ensuring that the evidence required is relevant, rigorous and proportionate to the actual risks of each product."

The quote, from Yu's announcement of the publication, is aimed squarely at the objection the paper will face. Food safety agencies exist to be conservative, and any proposal that shortens the path to market will be read as a pressure campaign by skeptics. The authors are betting that the opposite framing wins: animal feeding studies were designed for chemicals of unknown composition, and applying them to food made from well-characterized inputs in sterile bioreactors is precision theater, not rigor.

The economics of the approval tax

Step back and the story is really about cost structure. Cultivated meat startups talk endlessly about the cost of bioreactors, media and scale. Less discussed is the fixed regulatory tax that falls equally on a company with a billion-dollar facility and one with a pilot plant: every dossier, every market, every process change can carry a six-figure testing bill and a year of waiting.

A harmonized, lab-based framework attacks that tax in two ways. First, it makes evidence portable: a compositional analysis that satisfies Singapore should look similar to one that satisfies Bangkok. Second, it makes iteration affordable: reassessing one changed input rather than the whole product means companies can improve their processes the way software companies ship updates, incrementally, instead of freezing a design years before launch.

There are limits to what a paper can do. The forum has no authority to bind any regulator, and the history of food regulation is full of harmonization efforts that stalled at the first national veto. The EU's novel food process remains a cautionary tale: twenty precision fermentation products authorized, eighteen of them human milk oligosaccharides, and zero cultivated meat, with the only cultivated dossier under evaluation being Parima's duck cell biomass filed in July 2024. But a published, peer-reviewed framework with 30-plus contributors gives reform-minded regulators something they have lacked: a document to point at.

The cultivated meat industry has spent a decade trying to make the biology cheaper. This paper argues that the chemistry of approval deserves the same treatment. If it succeeds, the biggest unlock for cultivated meat in Asia will not be a better bioreactor. It will be a shorter queue.